Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis.

Cancers (Basel) · 2023 · PMC10741389 · PMID 38136304

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Discussion It is generally accepted that there are no differences in the conventional parameters of efficacy, whichever of the two agents (regorafenib or trifluridine/tipiracil) is used first, while some reports suggested that patients who received T after R showed a trend towards a longer PFS than those who received T before R [ 31 , 32 ].

also in 53,322 other papers

a positive trendno p-value reported

did not reach statistical significanceno p-value reported

However, in the univariate analysis of the R 3 to <6 months/T group, the metastatic locations did not reach statistical significance, but a positive trend was noted.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.